Episode Details
Back to Episodes
S21E25: Who Really Wins When Weed Goes Mainstream?
Description
Cannabis just moved from Schedule I to Schedule III — and the biggest implications have nothing to do with lifestyle or politics.
In this episode of Market Outsiders, Jenny Rae and Namaan break down what reclassification means for the market: who benefits, who loses, and why cannabis stocks dropped on “good” news.
They unpack the real unlocks behind the headlines — Medicare and Medicaid eligibility, federally funded research, banking access, and why Big Pharma, consumer giants, and even beer companies may now have the edge.
This is a regulatory shock case study: how one policy change reshapes competition, pricing power, supply chains, and long-term winners across healthcare and consumer markets.
Partner Links:
- Learn more about NordStellar's Threat Exposure Management Program; unlock 10% off with code SIMPLIFIED-10
Chapters:
01:05 — What Cannabis Reclassification Actually Changes
03:15 — Schedule I vs Schedule III: Why It Matters
05:45 — Banking, Taxes, and the Industry’s Hidden Constraints
08:20 — Medicare, Medicaid, and the Real Demand Unlock
11:10 — Why Cannabis Stocks Fell on “Good” News
13:30 — Big Pharma, Big Beer, and New Market Entrants
19:40 — Supply Chains, Compliance, and Rising Costs
25:00 — Who Wins, Who Loses, and What Comes Next
Free Consulting Prep Just Got a Whole Lot Better
Create a free MC account for access to step-by-step learning pathways, a brand new case prep course, and more. Download the MC app to prep anywhere.
Connect With Management Consulted
- Create a free MC account or download the MC app (Apple, Android) to start your prep today
- Schedule a free 15min consultation with the MC Team
- Watch the video version of the podcast on YouTube
- Follow us on LinkedIn, Instagram, and TikTok
- Join an upcoming live event – case interviews demos, expert panels, and more